SCHEMBL8225901

SCHEMBL8225901

CCOC(=O)[C@H]1CCN[C@H]1c1cc(NC(=O)OC)ccc1S(=O)(=O)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 4/20 0.35
KDM4E B2RXH2 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
PKM P14618 2/20 0.34
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
MAPT P10636 1/20 0.34
MMP2 P08253 2/20 0.33
MMP9 P14780 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8224166 1.00 KMT2A (0.43) KMT2AL3MBTL1LMNAKDM4ECA12
SCHEMBL8229014 0.90 KMT2A (0.44) KMT2AL3MBTL1LMNAKDM4ECA12
SCHEMBL8229018 0.90 KMT2A (0.44) KMT2AL3MBTL1LMNAKDM4ECA12
SCHEMBL8226789 0.90 KMT2A (0.44) KMT2AL3MBTL1LMNAKDM4ECA12
SCHEMBL8224294 0.90 KMT2A (0.44) KMT2AL3MBTL1LMNAKDM4ECA12
SCHEMBL8226819 0.89 APEX1 (0.34) KMT2AL3MBTL1LMNAKDM4ECA12
Hydrochloric Acid SCHEMBL3089327 0.86 ALDH1A1 (0.36) KMT2ALMNACYP1A2CYP2C19HTT
SCHEMBL8221416 0.81 PKM (0.44) KMT2ACA12CA1CA2CA9
SCHEMBL8263932 0.81 PKM (0.44) KMT2ACA12CA1CA2CA9
SCHEMBL8225004 0.81 PKM (0.44) KMT2ACA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061756-B1 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL MYERS SQUIBB CO (US) 2013-09-25 EP disclosed
US-8222453-B2 Benzamide factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 US disclosed
US-20100227894-A1 BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2010-09-09 US disclosed
WO-2007146719-A2 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227894-A1 BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F7, F9, F8 KMT2A 1210/4885L3MBTL1 2634/4885LMNA 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.